Drug Profile


Alternative Names: BGF MDI; Budesonide/glycopyrrolate/formoterol; Budesonide/PT 003; Formoterol/budesonide/glycopyrrolate; Formoterol/glycopyrrolate/budesonide; Glycopyrrolate/budesonide/formoterol; Glycopyrrolate/formoterol/budesonide; LAMA/LABA/ICS triple combination - Pearl Therapeutics; PT-003/budesonide; PT-010

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Pearl Therapeutics
  • Developer AstraZeneca; Pearl Therapeutics
  • Class Anti-inflammatories; Antiasthmatics; Antispasmodics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Asthma

Most Recent Events

  • 20 Mar 2017 Pearl Therapeutics plans a phase III trial for Chronic obstructive pulmonary disease (Combination therapy) (NCT03081247)
  • 14 Mar 2017 Pearl Therapeutics plans a phase I trial for Chronic obstructive pulmonary disease (In volunteers, Combination therapy) in China (NCT03075267)
  • 01 Aug 2015 Pearl Therapeutics initiated a phase III trial for Chronic obstructive pulmonary disease in USA (NCT02536508)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top